CD274 and neoplasm: Anti-PD-1 antibody is thought to activate tumour-specific T cells by interfering with the ligation of PD-1 on tumour-specific T cells and PD-L1/L2 on tumour cells in both priming and effector phases.11 Thus, it has been suggested that anti-PD-1 therapy modulates systemic host-immune reactions and exerts an anti-tumour effect.